Abstract: Methods of forming a silica-based products are disclosed. One method comprises: (a) providing a silica containing precursor (SCP) contained in solution that has a pH less than or equal to a pH of 7; (b) optionally doping the SCP with one or more metal species, wherein said doping occurs when the solution has a pH less than or equal to a pH of 7; (c) adjusting the pH of the solution to greater than 7; (d) adding an effective amount of salt to the solution so that the conductivity of the solution is greater than or equal to 4 mS, wherein said addition occurs prior to, simultaneous with, or after the pH adjustment in step 1c; (e) optionally filtering and drying the SCP; and (f) optionally reacting the dried product from step e with a functional group and optionally wherein the resultant functionalized dried product is at least one of the following: a functionalized metal oxide-doped or metal sulfide-doped silica product.

Abstract: Affords Group-III nitride single-crystal ingots and III-nitride single-crystal substrates manufactured utilizing the ingots, as well as methods of manufacturing III-nitride single-crystal ingots and methods of manufacturing III-nitride single-crystal substrates, wherein the incidence of cracking during length-extending growth is reduced. Characterized by including a step of etching the edge surface of a base substrate, and a step of epitaxially growing onto the base substrate hexagonal-system III-nitride monocrystal having crystallographic planes on its side surfaces. In order to reduce occurrences of cracking during length-extending growth of the ingot, depositing-out of polycrystal and out-of-plane oriented crystal onto the periphery of the monocrystal must be controlled.

Abstract: A method of preparing purified barium nitrate includes precipitating barium nitrate crystals from a solution, and washing the barium nitrate crystals with an aqueous solution including at least 10 wt % nitric acid.

Abstract: An active material of the present invention has fine pores formed in the interlayer of a carbon material capable of exhibiting electrochemical double layer capacitance. The fine pores are formed by forming an oxidized graphite structure combined with oxygen in the interlayer of a part or whole of the carbon material containing soft carbon and then removing a part or whole of oxygen in the interlayer. A method for producing an energy storage active material for use in an electrochemical double layer capacitor comprises pre-treating a carbon material through heat treatment and oxidizing the pre-treated carbon material using an oxidant. The method further comprises reducing the oxidized carbon material through heat treatment. The interlayer distances of an active material for respective steps, measured by a powder X-ray diffraction method, are 0.33˜0.36 nm in the pre-treatment step, 0.5˜2.1 nm in the oxidation step, and 0.34˜0.5 nm in the reduction step.

Abstract: The present invention relates to single walled and multi-walled carbon nanotubes (CNTs), functionalized CNTs and carbon nanotube composites with controlled properties, to a method for aerosol synthesis of single walled and multi-walled carbon nanotubes, functionalized CNTs and carbon nanotube composites with controlled properties from pre-made catalyst particles and a carbon source in the presence of reagents and additives, to functional, matrix and composite materials composed thereof and structures and devices fabricated from the same in continuous or batch CNT reactors. The present invention allows all or part of the processes of synthesis of CNTs, their purification, doping, functionalization, coating, mixing and deposition to be combined in one continuous procedure and in which the catalyst synthesis, the CNT synthesis, and their functionalization, doping, coating, mixing and deposition can be separately controlled.

Abstract: The present disclosure is directed to a method of producing metallic single-wall carbon nanotubes by treatment of carbon nanotube producing catalysts to obtain the desired catalyst particle size to produce predominantly metallic single wall carbon nanotubes. The treatment of the carbon nanotube producing catalyst particles involves contacting the catalyst particles with a mixture of an inert gas, like He, a reductant, such as H2, and an adsorbate, like water, at an elevated temperature range, for example, at 500° C. to 860° C., for a sufficient time to obtain the catalyst particle size. In some of the present methods, the preferential growth of nanotubes with metallic conductivity of up to 91% has been demonstrated.

Abstract: A process and an installation for producing a synthesis gas by catalytic steam reforming of a charge of hydrocarbons is provided.

Abstract: A catalyst has a long life span and efficiently separates hydrogen from water. A first metal element (Ni, Pd, Pt) for cutting the combination of hydrogen and oxygen and a second metal element (Cr, Mo, W, Fe) for helping the function of the first metal element are melted in alkaline metal hydroxide or alkaline earth metal hydroxide to make a mixture heated at a temperature above the melting point of the hydroxide to eject fine particles from the liquid surface, bringing steam into contact with the fine particles. Instead of this, a mixture of alkaline metal hydroxide and metal oxide is heated at a temperature above the melting point of the alkaline metal hydroxide to make metal compound in which at least two kinds of metal elements are melted, and fine particles are ejected from the surface of the metal compound to be brought into contact with steam.

Abstract: Radiolabeled tracers for sodium/glucose cotransporters (SGLTs), their synthesis, and their use are provided. The tracers are methyl or ethyl pyranosides having an equatorial hydroxyl group at carbon-2 and a C 1 preferred conformation, radiolabeled with 18F, 123I, or 124I, or free hexoses radiolabeled with 18F, 123I, or 124. Also provided are in vivo and in vitro techniques for using these and other tracers as analytical and diagnostic tools to study glucose transport, in health and disease, and to evaluate therapeutic interventions.

Abstract: The present invention is directed to radiolabeled pyrimidinone compounds of general structural formula I which are useful as radiotracers for quantitative imaging of PDE10 in mammals.

Abstract: The present invention provides radioactive gallium complexes which comprise DOTA-biotin conjugates, incorporating a linker group. Also described are radiopharmaceutical compositions, and methods and uses of the complexes for in vivo imaging involving pre-targeting with avidin.

Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.

Abstract: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.

Abstract: The invention provides, inter alia, methods for methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with APCDD1 overexpression.

Abstract: Novel, non-toxic cobalt-based contrast and imaging agents for use in enhanced medical imaging modalities and processes are described, as well the manufacture of markers containing such contrast agents is described, and uses for such imaging markers and contrast agents in a variety of therapeutic applications and devices.

Abstract: The present invention relates to a heating or warming composition that may be delivered orally or to the skin or mucous membranes. The composition contains a warming agent in combination with a cooling agent. The warming agent and cooling agent may be provided in one composition or they may be provided separately in distinct formulations separated over time or geographically. The present invention also extends to methods of providing a heating sensation as well as to products for oral or skin or mucous membrane delivery that contain such a warming composition or that contain a warming agent in combination with a cooling agent. Such products include food products, beverages, chewing gums, confections, cosmetics, lotions, creams and the like containing such a warming composition.

Abstract: The present application relates to novel antimicrobial compositions and methods of using said antimicrobial compositions for inhibiting and treating microbial growth, microbial infections, inflammatory diseases, viral diseases, cardiovascular diseases, diabetes and/or conditions that may be regulated or associated with microbial infections, such as cancer.

Abstract: The present application relates to novel antimicrobial compositions and methods of using said antimicrobial compositions for inhibiting and treating microbial growth, microbial infections, inflammatory diseases, viral diseases, cardiovascular diseases, diabetes and/or conditions that may be regulated or associated with microbial infections, such as cancer.

Abstract: The present invention relates to silicone compounds which have photoprotective properties and personal care compositions comprising the same. The present inventors, in developing a sunscreen that gives protection against both UV radiation and visible radiation, found that when a certain moiety generally occurring in nature i.e. hydroxyanthraquinone having uv-visible absorption activity are attached to crosslinked silicone polymers they provide not only the desired photoprotection but also excellent spreadability on skin.

Abstract: The present invention provides a curable resin composition for coating natural or artificial nails, which in particular exhibits an excellent appearance after coating, high water and scratch resistances, and low levels of odor, damage to nails, and dermal irritancy, resulting in a high level of safety to human bodies and superior storage stability. The curable resin composition for coating a natural or artificial nail of the present invention comprises (A) an aqueous emulsion of a polymer having functional groups polymerizable by exposure to active energy radiation, (B) polyethylene glycol, and (C) a photo radical initiator containing no nitrogen atom in its molecule.

Abstract: Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor is represented by general formula (1) (excluding clotrimazole) and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent.

Abstract: The present invention relates to compositions comprising 1-hydroxyl 3,5-bis(4?hydroxyl styryl)benzene or a cosmetically acceptable salt thereof, and methods of treating human skin and signs of skin aging using said compositions.

Abstract: The invention relates to cosmetic compositions comprising a black color subtractive mixture consisting of one blue pigment (ferric ammonium ferrocyanide and/or ultramarine blue), at least one yellow organic pigment and at least one red organic pigment, which are mixed homogeneously, said mixture having a very dark black color.

Abstract: The present invention relates to a cosmetic composition and method for making up and/or enhancing the appearance of a keratinous substrate, comprising at least one supramolecular polymer, at least one detackifying ingredient which is a hyperbranched functional polymer, at least one fatty phase ingredient(s), at least one light silicone fluid other than the fatty phase ingredient(s), and at least one copolymer containing a silicone resin segment and a fluid silicone segment. The compositions of the present invention may optionally contain at least one functional filler, at least one wax and at least one colorant.

Abstract: An aqueous and/or aqueous alcoholic leave-in composition to reduce the time to dry wet hair containing (a) at least one wetting agent having a Draves wetting value of 100 seconds of less selected in an amount sufficient to enhance the hydrophobicity of hair thereby causing water to dewet the hair, and optionally (b) at least one volatile selected from the group consisting of alcohols, dimethicone, trimethicone, and cyclomethicone and a method of shortening the time to dry wet hair.

Abstract: The present disclosure relates to novel cosmetic compositions comprising, in a cosmetically acceptable medium: (i)—at least one cationic polymer produced by polymerization of a monomer mixture comprising: a) at least one vinyl monomer substituted with at least one amino group, b) at least one hydrophobic nonionic vinyl monomer, and c) at least one associative vinyl monomer, and e) at least one hydroxylated nonionic vinyl monomer, and (ii)—at least one amino silicone chosen from a) amino silicones comprising at least one primary amine function of formula (VI): wherein R, R?, and R?, which may be identical or different, are chosen from C1-C4 alkyl radicals, C1-C4 alkoxy radicals, and OH; A and B are independently chosen from linear and branched C2-C8 alkylene radicals, with the proviso that R and R? are not simultaneously hydroxyl groups, A is chosen from C3-C6 alkylene radicals; B is chosen from C2-C4 alkylene radicals; and m and n are integers that depend on the molecular weight and whose s

Abstract: Disclosed are mascara compositions containing a first acrylates copolymer having a relatively low glass transition temperature (Tg) which is less than about 0° C., a second acrylates copolymer having a relatively high glass transition temperature which is between about 0° C. and less than about 60° C., wherein a mixture of the first and second acrylates copolymers has a Tg less than about 20° C., and a solvent. Also disclosed are methods for making the mascara and applying them to keratinous tissue such as eyelashes in order to enhance their appearance.

Abstract: The present invention relates to cosmetic use, by topic application on the skin of at least one protoberberine, with exception of berberine, or a vegetable extract containing it, as an active substance reducing activity of the pilosebaceous unit, preferably inhibiting activity of the pilosebaceous unit. In particular, the invention relates to cosmetic use of at least one protoberberine, with exception of berberine, or a vegetable extract containing it, as an agent reducing, preferably inhibiting the growth of hairs of the face and/or the body, and/or seborrheic activity of the sebaceous glands. The invention also relates to a cosmetic composition comprising in a dermatologically acceptable carrier, at least one protoberberine, with exception of berberine, or a vegetable extract containing protoberberines, as an active substance, which reduces, preferably inhibits the skin's pilosebaceous unit activity.

Abstract: Conjugates are provided herein which comprise a protein attached to at least two polymeric moieties, at least one of which exhibits reverse thermal gelation. The conjugates are suitable for being cross-linked by non-covalent and/or covalent cross-linking. Compositions-of-matter comprising cross-linked conjugates are provided herein, as well as processes for producing same. Methods of controlling a physical property of compositions-of-matter are also provided herein. The conjugates and compositions-of-matter may be used for various applications, such as cell growth, tissue formation, and treatment of disorders characterized by tissue damage or loss, as described herein.

Abstract: The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients.

Abstract: One aspect of the present invention relates to methods of sealing a wound or tissue plane or filling a void space, or securing meshes, films or other devices within the body. In certain embodiments, the wound is an ophthalmic, pleural or dural wound, or a hernia repair mesh. Remarkably, disclosed herein is the discovery that the use of certain crosslinkers in combination with polyalkyleneimines at specific concentrations can result in hydrogels with tunable degradation properties.

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Abstract: An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid.

Abstract: This invention provides crystalline recombinant interferon (rSIFN-co (SEQ ID NO: 1)) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-?2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structural model of said interferon useful for drug screening and/or drug design, and mimetics of said interferon.

Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.

Abstract: The present invention relates to compositions for the oral and vaginal administration of human Lactobacilli and uses thereof for physiologic restoration of the vaginal flora, physiologic maintenance of Lactobacillus flora in pathologic deficiency to produce Lactobacilli, treatment of asymptomatic bacterial vaginosis and prevention of preterm delivery caused through bacterial vaginosis.

Abstract: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.

Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

Abstract: Agents and methods to alter rAAV transduction are provided.

Abstract: Novel simian adenovirus 41 and two isolates thereof are described. Various uses of these isolates, including construction of a recombinant vector which comprises simian adenovirus 41 sequences and a heterologous gene under the control of regulatory sequences are provided. A cell line which expresses simian adenovirus 41 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.

Abstract: The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.

Abstract: The invention relates to a dietary supplement that promotes proper ingestion and proper digestion of animal and/or vegetable proteins. The supplement comprises an enzyme mixture containing amylase, lactase and bromelain in the following dosage by weight: 15 mg to 90 mg amylase, 18 mg to 90 mg lactase and 6 mg to 80 mg bromelain.

Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.

Abstract: The present invention describes methods and tools for preparing a population of monodisperse polymer microparticles, which are of particular interest in the field of drug delivery.

Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.

Abstract: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.

Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.

Abstract: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms.